Small molecule inhibitors of the GDP KRAS-OFF state are emerging, such as sotorasib (LUMAKRAS) and adagrasib (KRAZATI) for KRASG12C mutant cancers, and MRTX1133 for KRASG12D mutant cancers (Wang et al, 2022). Here, KRAS is linked to cancer.